| Literature DB >> 21612933 |
Virginie Andrzejak1, Giulio G Muccioli, Mathilde Body-Malapel, Jamal El Bakali, Madjid Djouina, Nicolas Renault, Philippe Chavatte, Pierre Desreumaux, Didier M Lambert, Régis Millet.
Abstract
Growing evidence suggests a role for the endocannabinoid (EC) system, in intestinal inflammation and compounds inhibiting anandamide degradation offer a promising therapeutic option for the treatment of inflammatory bowel diseases. In this paper, we report the first series of carboxamides derivatives possessing FAAH inhibitory activities. Among them, compound 39 displayed significant inhibitory FAAH activity (IC(50)=0.088 μM) and reduced colitis induced by intrarectal administration of TNBS.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21612933 DOI： 10.1016/j.bmc.2011.04.057
Source DB: PubMed Journal: Bioorg Med Chem ISSN： 0968-0896 Impact factor: 3.641